Celltrion’s Remsima presented clinical study result led by Norwegian government
A result of the long-term clinical trial to research the Remsima’s substitute administration, ‘NOR-SWITCH Study’ was released at the United European Gastroenterology Week(UEGW) on the 18th(local time) in Vienna, Austria.
Conducted by the Norwegian healthcare authorities, the NOR_SWITCH Study is...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
